On April 15, 2025, President Trump signed an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The order includes various provisions that are relevant to the pharmaceutical industry,...more
4/22/2025
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Executive Orders ,
Inflation Reduction Act (IRA) ,
Life Sciences ,
Medicare ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Legislation ,
Regulatory Reform ,
Tariffs ,
Trump Administration
The proposed cuts would place a 15% indirect cost rate on all new and existing grant awards received by research institutions and universities....more
3/5/2025
/ Colleges ,
Department of Health and Human Services (HHS) ,
Executive Orders ,
Federal Funding ,
Federal Grants ,
Government Agencies ,
Grants ,
Life Sciences ,
Medical Research ,
National Institute of Health (NIH) ,
Preliminary Injunctions ,
State and Local Government ,
Trump Administration ,
Universities
Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of our Connected With Latham podcast series,...more
Welcome to the latest edition of our Healthcare & Life Sciences Market Update, in which we explore the evolving landscape of investment trends, regulatory challenges, and strategic opportunities shaping the global market....more